FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR
FRA:4AB (3/7/2025, 7:00:00 PM)
196.38
+2.18 (+1.12%)
The current stock price of 4AB.DE is 196.38 EUR. In the past month the price increased by 5.49%. In the past year, price increased by 18.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B | ||
1MRNA.MI | MODERNA INC | N/A | 12.34B |
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 50000
Company Website: https://www.abbvie.com/
Investor Relations: https://investors.abbvie.com
Phone: 18479327900
The current stock price of 4AB.DE is 196.38 EUR. The price increased by 1.12% in the last trading session.
The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.
4AB.DE stock is listed on the Deutsche Boerse Ag exchange.
33 analysts have analysed 4AB.DE and the average price target is 200.78 EUR. This implies a price increase of 2.24% is expected in the next year compared to the current price of 196.38. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABBVIE INC (4AB.DE) has a market capitalization of 346.68B EUR. This makes 4AB.DE a Mega Cap stock.
ABBVIE INC (4AB.DE) currently has 50000 employees.
ABBVIE INC (4AB.DE) has a support level at 196.37. Check the full technical report for a detailed analysis of 4AB.DE support and resistance levels.
The Revenue of ABBVIE INC (4AB.DE) is expected to grow by 6.13% in the next year. Check the estimates tab for more information on the 4AB.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABBVIE INC (4AB.DE) has a dividend yield of 3.11%. The yearly dividend amount is currently 5.75. Check the full fundamental report for a detailed analysis of 4AB.DE dividend history, reliability and sustainability.
ABBVIE INC (4AB.DE) will report earnings on 2025-04-24, before the market open.
The PE ratio for ABBVIE INC (4AB.DE) is 21.07. This is based on the reported non-GAAP earnings per share of 9.32 and the current share price of 196.38 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 4AB.DE.
ChartMill assigns a technical rating of 9 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is one of the better performing stocks in the market, outperforming 88.57% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. While 4AB.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 9.32. The EPS decreased by -8.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 7.52% | ||
ROA | 3.14% | ||
ROE | 127.46% | ||
Debt/Equity | 18.15 |
ChartMill assigns a Buy % Consensus number of 80% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 23.75% and a revenue growth 6.13% for 4AB.DE